Trial Profile
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 04 Mar 2024
Price :
$35
*
At a glance
- Drugs Tazemetostat (Primary)
- Indications B-cell lymphoma; CNS cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Histiocytosis; Mantle-cell lymphoma; Mesothelioma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Rhabdoid tumour; Solid tumours; Synovial sarcoma
- Focus Adverse reactions
- Acronyms TRuST
- Sponsors Epizyme
- 24 Feb 2024 This trial has been completed in Belgium, According to Eudra record.
- 29 Dec 2023 Status changed from active, no longer recruiting to recruiting.
- 18 Aug 2023 Planned End Date changed from 1 Dec 2024 to 31 Dec 2024.